| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/20/2009 | CA2714198A1 Methods of making nucleoside tetraphosphate analogs |
| 08/20/2009 | CA2714110A1 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof |
| 08/20/2009 | CA2714087A1 Inhibitors of checkpoint kinases |
| 08/20/2009 | CA2714049A1 Novel 17.beta. lupane derivatives |
| 08/20/2009 | CA2713713A1 Piperidine sulfonamide derivatives |
| 08/20/2009 | CA2713378A1 3-alkyl-piperazine derivatives and uses thereof |
| 08/20/2009 | CA2713288A1 Compounds with mdr1-inverse activity |
| 08/20/2009 | CA2713112A1 Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
| 08/20/2009 | CA2712946A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 08/20/2009 | CA2712832A1 Implantable products comprising nanoparticles |
| 08/20/2009 | CA2711757A1 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| 08/20/2009 | CA2708246A1 Compositions for and methods of enhancing the immune response to antigens |
| 08/20/2009 | CA2703866A1 Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
| 08/19/2009 | EP2090654A1 PARTIAL FRAGMENT OF REIC/Dkk-3 GENE AND THERAPEUTIC AGENT FOR CANCER CONTAINING THE SAME |
| 08/19/2009 | EP2090607A1 Polymeric derivative of nucleic acid metabolic antagonist |
| 08/19/2009 | EP2090579A1 Substituted heteroarylamide diazepinopyrimidone derivatives |
| 08/19/2009 | EP2090578A1 Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| 08/19/2009 | EP2090577A2 Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| 08/19/2009 | EP2090576A1 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| 08/19/2009 | EP2090575A1 Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives |
| 08/19/2009 | EP2090571A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
| 08/19/2009 | EP2090566A2 Certain phenylacetic acids and derivatives |
| 08/19/2009 | EP2090334A2 Imidazole based compounds, compositions comprising them and methods of their use |
| 08/19/2009 | EP2090317A1 Method of preventing or treating diabetes |
| 08/19/2009 | EP2090314A1 Ophthalmic aqeous liquid preparation |
| 08/19/2009 | EP2090312A1 (S,S) reboxetine for treating attention deficit disorder |
| 08/19/2009 | EP2090311A1 Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| 08/19/2009 | EP2090310A1 Method for prevention of coloration in donepezil-containing skin adhesive preparation, and method for reducing the production of donepezil analogue in donepezil-containing skin adhesive preparation |
| 08/19/2009 | EP2090309A1 Use of thiazole inhibitors of fatty acid oxidation of formula (I) for the treatment of Alzheimer's disease and other neurological conditions |
| 08/19/2009 | EP2090308A1 Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
| 08/19/2009 | EP2090307A1 Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
| 08/19/2009 | EP2090306A1 Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| 08/19/2009 | EP2090305A1 Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome |
| 08/19/2009 | EP2090304A2 Use of sugar phosphates, sugar phosphate analogues, amino acids and/or amino acid analogues for modulating the glycose-enzyme complex, the malate aspartate shuttle and/or transaminases |
| 08/19/2009 | EP2090303A1 Association of a sinus current inhibitor if and a beta blocker |
| 08/19/2009 | EP2090302A1 Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic |
| 08/19/2009 | EP2090301A1 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanon und its use in cosmetic and pharmaceutical preparations |
| 08/19/2009 | EP2090300A1 Sustained release preparation |
| 08/19/2009 | EP2090299A2 Extended Release Gliclazide Formulations |
| 08/19/2009 | EP2090297A1 Formulations of flibanserin |
| 08/19/2009 | EP2090182A1 Method for improving flavor of astaxanthin-containing extract |
| 08/19/2009 | EP2090177A1 Food products having enhanced cocoa polyphenol content |
| 08/19/2009 | EP2090176A1 Postprandial hyperglycemia-improving agent |
| 08/19/2009 | EP2090172A1 Dough composition |
| 08/19/2009 | EP2090169A1 Nucleic acid-degrading agent and method for degradation of nucleic acid |
| 08/19/2009 | EP2090165A2 Antifungal composition with enhanced bioavailability |
| 08/19/2009 | EP2089505A1 Reduced-hangover alcoholic beverage |
| 08/19/2009 | EP2089438A1 Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety |
| 08/19/2009 | EP2089409A1 Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprision thereof and a method for the treatment of a rho-gtpase cell protein-mediated condition |
| 08/19/2009 | EP2089404A1 Crystalline forms of zoledronic acid |
| 08/19/2009 | EP2089403A1 (1r,6s)-2-azabicyclo[4.3.0] nonane-8,8-diphosphonic acid and its use in treating or preventing bone disorders, for example, osteoporosis or paget's disease |
| 08/19/2009 | EP2089401A1 Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| 08/19/2009 | EP2089397A1 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists |
| 08/19/2009 | EP2089395A2 New isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities |
| 08/19/2009 | EP2089393A1 Heterocyclic compounds as antiinflammatory agents |
| 08/19/2009 | EP2089392A2 3-(dihydro-1h-pyrazolo ý4,3-d¨pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
| 08/19/2009 | EP2089389A2 Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity |
| 08/19/2009 | EP2089388A2 Process for the synthesis of moxifloxacin hydrochloride |
| 08/19/2009 | EP2089387A1 Indolizine derivatives and their use as antidiabetics |
| 08/19/2009 | EP2089386A2 Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 08/19/2009 | EP2089384A2 2-(piperidin-4-yl)-4-phenoxy-or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors |
| 08/19/2009 | EP2089383A1 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| 08/19/2009 | EP2089382A1 Substituted diazepan compounds as orexin receptor antagonists |
| 08/19/2009 | EP2089381A1 Indoles which act as via receptor antagonists |
| 08/19/2009 | EP2089380A1 Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors |
| 08/19/2009 | EP2089379A2 A novel crystalline form of lansoprazole |
| 08/19/2009 | EP2089378A1 Short-acting benzodiazepine salts and their polymorphic forms |
| 08/19/2009 | EP2089376A1 (r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use |
| 08/19/2009 | EP2089375A2 A method of purification of (s)-n-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride (duloxetine) |
| 08/19/2009 | EP2089369A2 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
| 08/19/2009 | EP2089368A1 Diaminocyclohexane and diaminocyclopentane derivatives |
| 08/19/2009 | EP2089367A1 Pyrazoline compounds as mineralocorticoid receptor antagonists |
| 08/19/2009 | EP2089364A1 Pyridinone compounds |
| 08/19/2009 | EP2089363A1 Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide |
| 08/19/2009 | EP2089361A2 Inhibitors of sodium glucose co-transporter 2 and methods of their use |
| 08/19/2009 | EP2089356A1 Salt of aliskiren with orotic acid |
| 08/19/2009 | EP2089350A1 Crystalline potassium salt of lipoxin a4 analogs |
| 08/19/2009 | EP2089110A2 Acetylene derivatives and their use for binding and imaging amyloid plaques |
| 08/19/2009 | EP2089061A1 Inhibition of sox9 function fn the treatment of proteogl ycan-associated pathophysiological conditions |
| 08/19/2009 | EP2089060A1 Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| 08/19/2009 | EP2089037A2 Mixture and method for reducing cholesterol using hydrophobic microparticles |
| 08/19/2009 | EP2089036A1 Methods of treating an ocular allergy with low dose dexamethasone |
| 08/19/2009 | EP2089035A1 Method for treating blepharitis |
| 08/19/2009 | EP2089034A1 Novel uses |
| 08/19/2009 | EP2089033A2 Stroke recovery |
| 08/19/2009 | EP2089032A1 A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect |
| 08/19/2009 | EP2089031A1 Reduction of overweight or obesity |
| 08/19/2009 | EP2089030A2 Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| 08/19/2009 | EP2089029A2 Pak modulators |
| 08/19/2009 | EP2089028A2 Method for treating delirium |
| 08/19/2009 | EP2089027A1 Use of iap inhibitors for the treatment of acute myeloid leukemia |
| 08/19/2009 | EP2089026A2 Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy |
| 08/19/2009 | EP2089025A1 Thuggacin-type macrolide antibiotics and their use as antimycobacterial agents |
| 08/19/2009 | EP2089024A2 Combination of iap inhibitors and flt3 inhibitors |
| 08/19/2009 | EP2089023A2 Methods of treating neuropathic pain with agonists of ppar-gamma |
| 08/19/2009 | EP2089022A2 Composition containing a mixture of antidepressants for treating premature ejaculation |
| 08/19/2009 | EP2089021A2 Use of carboxyamidotriazole (cai) orotate in macular degeneration |
| 08/19/2009 | EP2089020A1 Macrocyclic peptides as hepatitis c virus inhibitors |
| 08/19/2009 | EP2089019A2 Polymorphs of a hydroisoindoline tachykinin receptor antagonist |
| 08/19/2009 | EP2089018A2 Methods of treating cognitive impairment and dementia |